1	U-shaped Association Between Mean Platelet Volume And Short-term
2	Survival In Chinese Patients With Heart Failure
3	Yuan-lei Huang ^a , Qi Zhou ^a , Tao Zheng ^a *
4	The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang,
5	China
6	Yuan-lei Huang
7	Department: Department of Cardiovascular Medicine
8	Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
9	Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province
10	Qi Zhou
11	Department: Department of Cardiovascular Medicine
12	Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
13	Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province
14	Corresponding Author:
15	Tao Zheng
16	Department: Department of Cardiovascular Medicine
17	Hospital: The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine
18	Street Name & Number: No.50, North Baoshan Road, Yunyan District, Guizhou Province
19	Tel:8615985184796
20	E-mail: oulaosisonzhengtao@163.com
21	
22	
23	
24	
26 NC	TE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Keywords: Mean platelet volume, Association, Nonlinearity, Non-obese, 6 months all-cause
 mortality

Background: Mean Platelet Volume (MPV) has been proposed as a potential predictor of increased mortality risk at 6 months among Chinese patients with heart failure (HF). However, the current evidence supporting this association is limited.

Methods: This study aimed to investigate the relationship between MPV and HF short-term survival status. The data was obtained from a publicly accessible HF database in Zigong, Sichuan, and included information on 2008 Chinese patients. Baseline MPV was considered as the exposure while HF short-term survival status was the outcome. Two models, a binary logistic regression model and a two-piecewise linear model, were used to analyze the data.

37 **Results:** The study revealed a U-shaped relationship between MPV and all-cause mortality in 38 HF patients. When MPV levels were less than 9.8, every unit increase in MPV was associated 39 with a 91% reduction (RR: 0.09; 95% CI: 0.03-0.24; P=0.0001) in the risk of death over the next six months. In contrast, at MPV levels above 9.8, each unit increase in MPV was linked to a 27% 40 41 increase (RR: 1.27; 95% CI: 1.01-1.61; P=0.0434) in the probability of dving within the same period. Stratification by obesity status revealed no significant association between MPV and death 42 43 in the obese population, while the same U-shaped association was observed among non-obese 44 participants.

45 **Conclusion:** The present study provides evidence of a U-shaped association between MPV 46 and short-term survival in Chinese patients with heart failure. These findings suggest that MPV 47 may serve as a potential prognostic marker for HF. However, further studies are needed to validate 48 these results and to explore the underlying mechanisms of this association. The observed U-49 shaped association did not apply to obese patients, suggesting that the effect of MPV on mortality 50 risk in HF patients may be influenced by body weight.

51 52

Introduction

53 The mean platelet volume (MPV) is a low-cost and easy-to-use blood count indicator that has 54 been suggested to play a critical role in platelet reactivity, inflammation, thrombosis, and heart 55 failure (HF) in previous studies(1-4). MPV is frequently used as a surrogate measure of platelet 56 function since it reflects both platelet size and activity, with larger platelets being associated with increased platelet aggregation, thromboxane production, platelet globulin release, and adhesion 57 58 molecule expression(5), Elevated MPV levels have been found in various disease states, 59 particularly in individuals with cardiovascular risk factors such as smoking, diabetes, obesity, 60 hypertension, and hyperlipidemia (6-10), indicating a need for careful cardiovascular risk assessment (11). Excessively high MPV levels are also associated with increased cardiovascular 61 62 disease risk and a poor prognosis.

63 HF is a worldwide pandemic disease that affects at least 26 million people worldwide and is increasing in prevalence as the population ages(12). In China, the number of people suffering from 64 HF has risen to 1.3 percent of the entire population(13). HF not only affects patients' quality of 65 life, but it also has a substantial financial impact on their families and society. According to 66 67 figures, HF accounts for 17 percent of total health expenditures for cardiovascular illness in the 68 United States(14), and total expenses are expected to rise by 127 percent between 2012 and 2030(15). Given the high mortality rate as well as the high financial burden caused by HF, 69 70 researchers have called HF "the last war of cardiovascular disease in the 21st century."(16, 17)

71 In recent years, MPV has piqued interest as a novel prognostic marker in patients with cardiovascular illness. However, evidence linking MPV to all-cause mortality in HF is lacking. 72 73 Budak et al. discovered a positive correlation between BNP and MPV(18). Furthermore, Kaya (19) and Kandis(2) reported that MPV upon admission was highly linked to in-hospital 74 75 mortality or death at 6 months, even after controlling for typical HF-related risk variables. 76 However, the majority of the information presented above has come from Western countries. 77 Besides, evidence on the link between MPV and short-term mortality in patients with HF in the 78 Chinese population is limited. Given China's vast population and rising HF prevalence, a better understanding of the relationship between MPV and short-term mortality risk in HF will be 79 80 beneficial for future predictive model-driven investigations. In light of this, this study offers a 81 secondary data analysis of a large sample HF database to investigate the relationship between 82 MPV and HF short-term prognosis. This study will also reveal these results.

83

85

84 **Participants and methods**

Data source and study design

This study is a retrospective cohort analysis based on publicly available and published data 86 87 obtained from clinical records of hospitalized inpatients with confirmed heart failure (HF) at the 88 Fourth People's Hospital in Zigong City, Sichuan Province, China, between December 2016 and June 2019. The data was downloaded from the PhysioNet website (10.13026/8a9e-w734), and a 89 90 detailed description of the dataset is available in the literature(20). The dataset has been de-91 identified to protect patient privacy. All data were extracted from the hospital's electronic medical record system, and the Ethics Committee of the Fourth People's Hospital of Zigong approved the 92 93 study (approval number: 2020-010). Patient informed consent was not required due to the 94 retrospective nature of the study and the anonymization of patient information. The outcome variable was 6-month all-cause mortality in HF patients, recorded as a dichotomous variable in the 95 96 original data, and the target independent variable was baseline MPV, recorded as a continuous 97 variable.

98 Study population

A sample of 2,008 individuals with HF was initially included in the dataset; however, after applying a set of screening criteria, 103 cases were excluded due to missing MPV data, leaving 1,905 cases for data analysis (for details, refer to Figure 1). The diagnosis of HF was made based on the criteria established by the European Society of Cardiology (ESC), and ICD codes were used to collect data on heart failure. The data provider has furnished specific details on the dataset.

104 Variables

105 Mean platelet volume

The mean platelet volume (MPV) was initially recorded as a continuous variable in the raw data. However, to investigate the stability of the results and ensure the robustness of the findings, we further transformed the MPV into a categorical variable based on quartiles. Specifically, the data was divided into four subgroups: Q1 (MPV range: 7.70-10.80, n=475), Q2 (MPV range: 10 00 12 00 475) Q2 (MPV range: 12 10 12 20 476) and Q4 (MPV range:

110 10.90-12.00, n=475), Q3 (MPV range: 12.10-13.20, n=476), and Q4 (MPV range: 13.30-17.60,

111 n=479). This approach allowed us to examine whether the effect values varied equidistantly and to

compare the consistency of the results obtained using MPV as a continuous versus a categoricalvariable.

114 **6-month all-cause death in HF patients**

3

The primary outcome measure of this study was six-month all-cause mortality in HF patients. 115 116 The original dataset provided information on the survival of HF patients at 6 months, represented

- 117 by a binary variable where 0 indicates survival and 1 indicates death.
- 118 Covariates
- 119 In this analysis, potential confounding variables were selected based on prior literature (21-120 23) that investigated risk factors associated with adverse outcomes in HF, as well as our clinical experience. The following variables were included: age and gender as demographic factors, 121 122 Charlson Comorbidity Index (CCI) as a measure of co-morbidities, statins, vasodilators, Ras blockers, and positive inotropes as pharmaceutical factors, high-sensitivity troponin, glomerular 123 124 filtration rate, and BNP as biomarkers, and BMI, NYHY classification, and number of
- 125 hospitalizations as illness features and anthropometric factors.
 - **Statistical analysis**

126 127 Continuous variables were expressed as mean \pm standard deviation (SD) (Gaussian 128 distribution) or median (range) (skewed distribution), and categorical variables were expressed as 129 numbers and percentages. The χ^2 (categorical variables), one-way ANOVA test (normal distribution), or Kruskal-Whallis H test (skewed distribution) were used to detect differences in 130 131 the distribution of baseline information across MPV subgroups (quartiles). We examined 132 univariate and multivariate binary logistic regression models to determine the association between the two. To observe the stability of changes in effect values under multiple strategy alterations, we 133 134 simultaneously display three models. The unadjusted model, or Model 1, does not account for covariates. The model with the fewest adjustments simply for sociodemographic components is 135 Model 2. Model 3 was the one that was completely factor-adjusted. because the binary logistic 136 137 regression model was unable to account for the nonlinear relationships. We utilized a generalized 138 additive model (GAM) and a smoothed curve fit to examine whether MPV was nonlinearly related to the probability of short-term death in HF (penalized spline method). If nonlinearity was 139 140 detected, we first used the recursive algorithm + bootstrapping to calculate the inflection point 141 extremely credible intervals, and then constructed two-piece binary logistic regression models on 142 both sides of the inflection point.

143 To illustrate the robustness of our results, we performed a sensitivity analysis. We 144 transformed mean platelet volume into a categorical variable based on quartiles and calculated p for trend. The aim was to see whether the association with outcome was consistent when MPV 145 146 was used as a continuous variable versus when it was used as a categorical variable.

R (http://www.r-project.org, R Foundation) and EmpowerStats

148 (http://www.empowerstats.com, X & Y Solutions, Inc., Boston, MA) are statistical applications 149 that were utilized to model the data. Statistical significance was defined as p-values of 0.05 (two-150 sided).

151

147

Results 152

153

Baseline characteristics of participants

Table 1 summarizes the baseline characteristics of all HF patients, categorized into quartiles 154 155 based on their MPV levels. Nearly 70% of the patients were below the age of 70. Significant differences were observed between the various MPV level groups (Q1-Q4) for eGFR, Ln BNP, 156 age, sex, use of Ras-Blockers, Inotropes, and diuretics (P < 0.05). Compared to the Q4 group, the 157 Q1, Q2, and Q3 groups had lower eGFR, Ln hs-Tnl, and LnBNP levels, and a smaller percentage 158

of females, a greater percentage of individuals over 70, and a lower percentage of RAS blockers, vasodilators, and diuretics. However, there was no statistically significant difference between the Q1-Q4 groups in terms of BMI, Charlson comorbidity score, NYHA classification, Vasodilator use, Statin use, number of hospitalizations, or 6-month all-cause mortality (P > 0.05).

163

Results of a binary logistic regression model's multivariate analysis

We employed a binary logistic regression model to examine the association between MPV and the 6-month risk of death in HF patients. Our analysis did not reveal a significant relationship between MPV and all-cause mortality (RR, 0.90; 95% CI: 0.77 to 1.06; P=0.1920). Furthermore, the minimally-adjusted (RR, 0.90, 95% CI: 0.77 to 1.06; P=0.2054) and fully-adjusted (RR, 0.94, 95% CI: 0.78 to 1.13; P=0.4888) models yielded identical results despite different adjustment procedures.

To verify the consistency of our findings, we categorized MPV into quartiles and calculated P for trend to compare with the results obtained from MPV as a continuous variable. As shown in Table 2, Our analysis revealed that RR had unequal variation across MPV subgroups (Q1-Q4), and P for trend values were discordant with those obtained using MPV as a continuous variable. These findings suggest that a non-linear relationship between MPV and all-cause mortality cannot be excluded.

176

Using generalized summation models to solve nonlinear issues

We found that the association between MPV and short-term all-cause mortality in HF 177 patients was non-linear using a generalized summation model and smoothed curve fitting (Figure 178 179 2). A two-piecewise linear model was developed on both sides of the inflection point, which was obtained using a recursive approach (Table 3). The non-linear results showed a U-shaped 180 181 relationship between MPV and 6-month mortality. Positive results were observed when MPV was 182 greater than 9.8 (RR, 1.27; 95% CI, 1.01 to 1.61), indicating that each 1fL increase in MPV was associated with a 27% increase in the risk of death. Negative results were found when MPV was 183 184 less than 9.8 (RR, 0.09; 95% CI, 0.03 to 0.24), indicating that each 1fL increase in MPV was 185 associated with a 91% reduction in the risk of death. Additionally, we stratified the individuals into different obesity categories and found no association between MPV and mortality in the obese 186 187 group. In contrast, in the non-obese population, the same U-shaped relationship between MPV and 188 6-month mortality was observed. At MPV ≤ 9.7 , the association between MPV and 6-month mortality was negative (RR, 0.08; 95% CI, 0.03 to 0.22), indicating that each 1fL increase in MPV 189 was associated with a 92% reduction in mortality risk; at MPV > 9.7 1fL, the association between 190 191 MPV and 6-month mortality was positive (RR, 1.29; 95% CI, 1.02 to 1.64), indicating that each 192 1fL increase in MPV was associated with a 29% increase in the risk of death.

193

194 Discussion

195 Our results imply that there is a U-shaped link between mean platelet volume and short-term mortality in HF in this cohort study. Both low and high MPV levels were linked to higher all-196 197 cause mortality in HF. However, this association did not hold true for obese individuals with HF. 198 This discovery offers a priori support for upcoming model-driven studies and may have 199 ramifications for how MPV levels are interpreted in clinical settings. As one of the most prevalent 200 clinical markers, understanding the true relationship between MPV and a poor prognosis in HF will aid in the development of more accurate models. Our findings will also assist clinicians in 201 202 making a more precise early evaluation of a patient's future risk linked with MPV, even though

this initial assessment is just approximate. Additionally, compared to other markers (blood
glucose, potassium, etc.), which might alter as a result of various situations, MPV is a more stable
measure.

Dilated chambers, poor contractility, local ventricular wall abnormalities, and combined atrial 206 207 fibrillation may promote thromboembolism by facilitating intracardiac blood flow arrest, which is 208 one of the possible mechanisms of poor prognosis in HF given that MPV is known to be a strong 209 indicator of platelet activation and congestive HF is characterized by an increase in 210 thromboembolic events(24). According to Jafri(25) et al., the coagulation system and platelet activation (increased plasma platelet factor 4, b-thromboglobulin) have been demonstrated to be 211 212 more susceptible in patients with severe HF and poor ejection fraction, The relationship between 213 platelet activation and a bad prognosis for HF stems from the possibility that these conditions may 214 contribute to the development of the disease by producing ischemic episodes, impairing left 215 ventricular function, and promoting intracardiac thrombosis. Chronic HF itself may increase the risk of platelet abnormalities and thrombosis through increased catecholamine release, 216 217 haemodynamic changes, vascular factors, nitric oxide, cytokines, and comorbid conditions(26-28). 218 The increased cytokine and catecholamine release observed in patients with severe HF is 219 associated with platelet activation and higher levels of MPV. Therefore, by reducing excessive 220 catecholaminergic activity, some studies have reduced MPV levels in patients with HF, thereby reducing mortality and hospitalization in HF(29, 30). In contrast, we discovered in our study that a 221 222 low MPV was likewise linked to a higher chance of passing away. The occurrence is currently 223 being reported for the first time, although no mechanisms have been found to explain it. Additionally, we discovered various MPV and mortality trends across states with obesity. We 224 225 hypothesize that the absence of a correlation between the two in the obese group may be due to a 226 lesser correlation between MPV and mortality in this cohort and a larger correlation between BMI and the risk of death. Of course, more data is required to support our findings given the tiny obese 227 228 population in our study.

229 While there are some similarities and some discrepancies between our results and those of 230 earlier studies(31, 32), they all point to the possibility of a higher MPV in HF. A previous 231 study(19) first demonstrated that MPV levels above 9.1 fL were an independent predictor of short-232 to mid-term HF-related hospitalization in outpatients with stable HFrEF in SR. However, that study had a small sample size and was restricted to HF patients with reduced ejection fraction, 233 234 whereas the current study was not. Kandis et al(2), conducted research. The best cutoff for 235 indicating elevated risk was > 10.5 fl. However, the cohort of patients in that study showed higher 236 levels of urea, serum creatinine, and systolic blood pressure in patients who passed away during follow-up, suggesting a stronger impact of the patient's initial systolic blood pressure, BUN levels, 237 238 and creatinine. In a cohort study(33) of the condition, an MPV value of > 9 fL was discovered to 239 be a potential predictor of rehospitalization and 1-year mortality in patients with decompensated 240 chronic HF in a cohort study. However, the study's participants were those with decompensated chronic HF who were hospitalized (NYHA class IV HF or acute pulmonary oedema). The study 241 has a limited sample size (n = 130) and no sensitivity analysis. By comparing the association 242 between the HF marker BNP and MPV, Budak et al. Error! Reference source not found. discovered that 243 244 MPV levels and brain natriuretic peptide (BNP) values were positively associated in patients referred to the emergency room with acute HF. According to the scientists, MPV can be a sign of 245 246 the severity and clinical condition of acute HF disease. Taking into account study design,

247 demographics, and other characteristics, we think the following factors are responsible for the248 results' variations.

Our clinical relevance can be seen in the following ways: The previous finding that high MPV is strongly associated with a high risk of death in HF patients also holds true for the Chinese population, according to our findings. In addition, we discovered that lower MPV is also strongly associated with a high risk of death in HF patients, a finding that has never been previously reported. This study suggests that in the future, doctors utilizing MPV as an assessment indicator may need to include a patient's obesity status when making clinical judgments or first prognosis assessments of patients. This offers fresh proof of MPV's clinical value.

256 257

Study advantages and limitations

We present a study with significant benefits, outlined below. Firstly, the use of large sample sizes enhances our statistical power. Secondly, the covariate information in our data is highly complete with few gaps. Thirdly, our work delves into non-linearity, providing further justification and insight. In comparison to previous studies, this allows for a greater understanding of the relationship between MPV and all-cause mortality. Lastly, we applied rigorous statistical corrections to address potential confounding variables, given the observational nature of our study.

However, some limitations should be acknowledged. Firstly, we only utilized baseline MPV
measurements upon admission and were therefore unable to track MPV trends throughout
hospitalization and their impact on outcomes. Secondly, the study was geographically and racially
restricted to the Chinese population. Lastly, despite accounting for known potential confounders,
residual confounders may still exist in any observational study.

Conclusion

Our study investigated the association between baseline mean platelet volume and 6-month all-cause mortality in patients with heart failure. We found a U-shaped association, where the allcause death rate increased at both low and high mean platelet volumes. However, we did not observe this connection in the population with obesity-related heart failure. These results have important clinical and public health implications, but additional prospective trials are needed to validate our findings and clarify their clinical implications.

276 277

278

269

Data Availability Statement

Publicly available datasets were analyzed in this study. This data can be found here: https://doi.org/10.13026/8a9e-w734.

279 280 281

Ethics Statement

Studies involving human subjects were reviewed and approved by the Ethics Committee of the Fourth People's Hospital of Zigong. In accordance with national legislation and institutional requirements, written informed consent for participation in this study was not required.

285 286

Competing interests

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Funding

289 290 Funding

291 This study was funded by the Science and Technology Support Plan of Guizhou Provincial 292 Department of Science and Technology in 2020 (Project No. Qianke Support [2021] General 064). 293 Acknowledgments 294 295 We thank Chen Chi for their guidance and review of this manuscript. 296 Authors' Contributions 297 298 Y-LH collected documents and wrote the manuscript. QZ also contributed equally to this 299 work. Y-LH and QZ are co-first authors. TZ reviewed and performed critical revision of the 300 manuscript. All authors have read and agreed to the published version of the manuscript. 301 References : 302 303 Stokes KY, Granger DN. Platelets: a critical link between inflammation and microvascular 1. dysfunction. J Physiol. 2012;590(5):1023-34. 304 305 2. Kandis H, Ozhan H, Ordu S, Erden I, Caglar O, Basar C, et al. The prognostic value of mean 306 platelet volume in decompensated heart failure. Emerg Med J. 2011;28(7):575-8. 307 3. Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. Eur Heart J. 2001;22(24):2233-308 42. 309 Chu SG, Becker RC, Berger PB, Bhatt DL, Eikelboom JW, Konkle B, et al. Mean platelet 4. 310 volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. J Thromb 311 Haemost. 2010;8(1):148-56. 312 5. Tsiara S, Elisaf M, Jagroop IA, Mikhailidis DP. Platelets as predictors of vascular risk: is there 313 a practical index of platelet activity? Clin Appl Thromb Hemost. 2003;9(3):177-90. 314 6. Pathansali R, Smith N, Bath P. Altered megakaryocyte-platelet haemostatic axis in 315 hypercholesterolaemia. Platelets. 2001;12(5):292-7. 316 7. Nadar S, Blann AD, Lip GY. Platelet morphology and plasma indices of platelet activation in 317 essential hypertension: effects of amlodipine-based antihypertensive therapy. Ann Med.

318 2004;36(7):552-7.

- 319 8. Kario K, Matsuo T, Nakao K. Cigarette smoking increases the mean platelet volume in
- 320 elderly patients with risk factors for atherosclerosis. Clin Lab Haematol. 1992;14(4):281-7.
- 321 9. Inoue H, Saito M, Kouchi K, Asahara SI, Nakamura F, Kido Y. Association between mean
- 322 platelet volume in the pathogenesis of type 2 diabetes mellitus and diabetic macrovascular
- 323 complications in Japanese patients. J Diabetes Investig. 2020;11(4):938-45.
- 324 10. Coban E, Ozdogan M, Yazicioglu G, Akcit F. The mean platelet volume in patients with
- 325 obesity. Int J Clin Pract. 2005;59(8):981-2.
- 326 11. Vizioli L, Muscari S, Muscari A. The relationship of mean platelet volume with the risk and
- 327 prognosis of cardiovascular diseases. Int J Clin Pract. 2009;63(10):1509-15.
- 328 12. Lund LH, Savarese G. Global Public Health Burden of Heart Failure. Cardiac Failure Review.
- 329 2017;03(01).
- 330 13. Sakata Y, Shimokawa H. Epidemiology of heart failure in Asia. Circ J. 2013;77(9):2209-17.
- 331 14. Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. Heart failure:
- 332 preventing disease and death worldwide. ESC Heart Fail. 2014;1(1):4-25.
- 333 15. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart
- 334 Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.
- 335 Circulation. 2016;133(4):e38-360.
- 336 16. Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure
- 337 therapies. Nat Rev Cardiol. 2013;10(6):338-54.
- 338 17. Cowie MR, Wood DA, Coats AJ, Thompson SG, Suresh V, Poole-Wilson PA, et al. Survival of
- patients with a new diagnosis of heart failure: a population based study. Heart. 2000;83(5):505-10.

- 340 18. Budak YU, Huysal K, Demirci H. Correlation between mean platelet volume and B-type
- 341 natriuretic peptide concentration in emergency patients with heart failure. Biochem Med (Zagreb).
- 342 2015;25(1):97-102.
- 343 19. Kaya H, Kutay Yildirimli M, Kurt R, Beton O, Birhan Yilmaz M. Mean Platelet Volume as a
- 344 Predictor of Heart Failure-Related Hospitalizations in Stable Heart Failure Outpatients with Sinus
- 345 Rhythm. Acta Cardiol Sin. 2017;33(3):292-300.
- 346 20. Zhang Z, Cao L, Chen R, Zhao Y, Lv L, Xu Z, et al. Electronic healthcare records and external
- 347 outcome data for hospitalized patients with heart failure. Sci Data. 2021;8(1):46.
- 348 21. Wang R, Cao Z, Li Y, Yu K. Mean platelet volume provides an additive value in differentiating
- 349 congestive heart failure from chronic obstructive pulmonary disease. Int J Cardiol. 2015;179:201-2.
- 350 22. Dahlen B, Schulz A, Gobel S, Trobs SO, Schwuchow-Thonke S, Spronk HM, et al. The impact
- of platelet indices on clinical outcome in heart failure: results from the MyoVasc study. ESC Heart Fail.
- 352 2021;8(4):2991-3001.
- 353 23. Cheng YL, Sung SH, Cheng HM, Hsu PF, Guo CY, Yu WC, et al. Prognostic Nutritional Index
- and the Risk of Mortality in Patients With Acute Heart Failure. J Am Heart Assoc. 2017;6(6).
- 355 24. Rich MW, Beckham V, Wittenberg C, Leven CL, Freedland KE, Carney RM. A multidisciplinary
- 356 intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J
- 357 Med. 1995;333(18):1190-5.
- 358 25. Moore EE, Moore HB, Kornblith LZ, Neal MD, Hoffman M, Mutch NJ, et al. Trauma-induced
- 359 coagulopathy. Nat Rev Dis Primers. 2021;7(1):30.
- 360 26. Stach K, Kalsch AI, Nguyen XD, Elmas E, Kralev S, Lang S, et al. 1alpha,25-dihydroxyvitamin
- 361 D3 attenuates platelet activation and the expression of VCAM-1 and MT1-MMP in human endothelial

362 cells. Cardiology. 2011;118(2):107-15.

- 363 27. Karabacak M, Dogan A, Aksoy F, Ozaydin M, Erdogan D, Karabacak P. Both carvedilol and
- 364 nebivolol may improve platelet function and prothrombotic state in patients with nonischemic heart
- 365 failure. Angiology. 2014;65(6):533-7.
- 366 28. Handtke S, Steil L, Greinacher A, Thiele T. Toward the Relevance of Platelet Subpopulations
- 367 for Transfusion Medicine. Front Med (Lausanne). 2018;5:17.
- 368 29. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, et al. Effect of carvedilol on
- 369 survival in severe chronic heart failure. N Engl J Med. 2001;344(22):1651-8.
- 370 30. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, et al.
- 371 Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital
- admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26(3):215-25.
- 373 31. Martinez-Quintana E, Rodriguez-Hernandez JL, Riano-Ruiz M, Rodriguez-Gonzalez F. Mean
- 374 platelet volume and major adverse cardiovascular events in congenital heart disease patients. Clin
- 375 Hemorheol Microcirc. 2019;72(4):327-37.
- 376 32. Demirin H, Ozhan H, Ucgun T, Celer A, Bulur S, Cil H, et al. Normal range of mean platelet
- volume in healthy subjects: Insight from a large epidemiologic study. Thromb Res. 2011;128(4):358-
- 378 **60**.
- 379 33. Andrei CL, Catana A, Sinescu CJ, Mirica A, Ceban O, Chioncel VP, et al. Mean Platelet
- 380 Volume: A Possible Predictor for Patients with Decompensated Chronic Heart Failure. Int J Gen Med.
- 381 2022;15:4131-40.
- 382

11



Figure 1





medRxiv preprint doi: https://doi.org/10.1101/2023.06.16.23291510; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



	volume(quartile)					
		01/7 70 10 80	Q2 (10.90-	Q3(12.10-	Q4 (13.30-	Pavalue
		Q1(7.70-10.80)	12.00)	13.20)	17.60)	r-value
	Ν	475	475	476	479	
medRxiv preprint (which was no	BMI, mean±SD, kg/m ² doi: https://doi.org/10.1101/2023.06.16.232915 ot certified by peer review) is the author/funde It is made available unde	21.37 ± 9.58 510; this version posted June 20, er, who has granted medRxiv a lice of a CC-BY 4.0 International licens	21.40 ± 3.99 2023. The copyright holder tense to display the preprint se .	23.22 ± 25.08 for this preprint in perpetuity.	21.37 ± 6.72	0.103
	Obesity					
	<28	452 (95.16%)	443 (93.26%)	442 (92.86%)	450 (93.95%)	
	>=28	23 (4.84%)	32 (6.74%)	34 (7.14%)	29 (6.05%)	
	Ln hs-Tnl , mean±SD	$\textbf{-2.86} \pm 1.38$	$\textbf{-2.78} \pm 1.44$	$\textbf{-2.73} \pm 1.50$	$\textbf{-2.98} \pm \textbf{1.38}$	0.043
	eGFR, mean±SD,	66 55 + 38 66	66 27 + 37 03	66 02 + 34 53	73 62 + 36 11	0.005
	mL/min/1.73 m ²	00.55 ± 58.00	00.27 ± 57.05	00.92 ± 54.55	75.02 ± 50.11	0.005
	Ln BNP, mean±SD	6.33 ± 1.25	6.61 ± 1.25	6.59 ± 1.23	6.63 ± 1.19	< 0.001
	Charles comorbidity	1.02 ± 0.02	1 86 ± 0.08	1.82 ± 0.06	1 82 + 0 00	0 281
	score,mean±SD	1.95 ± 0.92	1.80 ± 0.98	1.85 ± 0.90	1.85 ± 0.99	0.581
	Sex, n (%)					0.034
	Male	188 (39.58%)	207 (43.58%)	222 (46.64%)	183 (38.20%)	

Table 1 : Baseline characteristics of patients with HF grouped by mean platelet

 Female	287 (60.42%)	268 (56.42%)	254 (53.36%)	296 (61.80%)	
Age, n (%)					0.003
≤70 years old	102 (21.47%)	120 (25.26%)	132 (27.73%)	152 (31.73%)	
>70 years old	373 (78.53%)	355 (74.74%)	344 (72.27%)	327 (68.27%)	

	NYHA classification, n					0.655
	(%)					0.655
	Π	80 (16.84%)	86 (18.11%)	82 (17.23%)	84 (17.54%)	
	III	247 (52.00%)	237 (49.89%)	243 (51.05%)	265 (55.32%)	
	IV	148 (31.16%)	152 (32.00%)	151 (31.72%)	130 (27.14%)	
medRxiv preprint (which was no	doi: https://doi.org/10.1101/2023.06.16.23291510; t certified by peer review) is the author/funder, w	this version posted June 20, 2 ho has granted medRxiv a lice	023. The copyright holder f	or this preprint n perpetuity.		0.616
	No	160 (33.68%)	164 (34.53%)	146 (30.67%)	156 (32.57%)	
	Yes	315 (66.32%)	311 (65.47%)	330 (69.33%)	323 (67.43%)	
	Ras-Blocker use, n (%)					< 0.001
	No	56 (11.79%)	25 (5.26%)	34 (7.14%)	25 (5.22%)	
	Yes	419 (88.21%)	450 (94.74%)	442 (92.86%)	454 (94.78%)	
	Inotropes use, n (%)					< 0.001
	No	159 (33.47%)	134 (28.21%)	111 (23.32%)	106 (22.13%)	
	Yes	316 (66.53%)	341 (71.79%)	365 (76.68%)	373 (77.87%)	
	Diuretic use, n (%)					0.002
	No	16 (3.37%)	2 (0.42%)	10 (2.10%)	4 (0.84%)	
	Yes	459 (96.63%)	473 (99.58%)	466 (97.90%)	475 (99.16%)	

Statin use, n (%)



No 271 (57.29%) 277 (58.44%) 293 (61.81%) 279 (58.25%)

Yes 202 (42.71%) 197 (41.56%) 181 (38.19%) 200 (41.75%)

Num	ber of	f
-----	--------	---

0.254

	hospitalizations, n (%)					
	≤1	429 (90.32%)	440 (92.63%)	444 (93.28%)	447 (93.32%)	
	>1	46 (9.68%)	35 (7.37%)	32 (6.72%)	32 (6.68%)	
	6 months all-cause					0.274
	mortality, n (%)					0.374
medRxiv preprint doi: https://doi.org/10.1101/2023.06.16.23291510; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.						
	Death	18 (3.79%)	15 (3.16%)	9 (1.89%)	14 (2.92%)	

Note: The difference between the sample sum of each column and the total number shown in

Table 1 is due to missing data

Abbreviation:

BMI: body mass index

Hs-Tnl: High-sensitivity troponin I

BNP: B-type natriuretic peptide

NYHA: New York Heart Association

eGFR: estimated glomerular filtration rate

Table 2: The association between MPV and all-cause mortality using binary logistic

regression model

		Non-adjusted model RR, 95%CI, P value	Minimally-adjusted model RR, 95%CI, P value	Fully-adjusted model RR, 95%CI, P value
medRxiv prepr (which was	6 months all-cause mortality int doi: https://doi.org/10.1101/2023.06.16.23291510; this not certified by peer review) is the author/funder, who	s version posted June 20, 2023. The copyright he has granted medRxiv a license to display the pre	older for this preprint eprint in perpetuity.	
	MPV (continuous variable)	0.90 (0.77, 1.06) 0.1920	0.90 (0.77, 1.06) 0.2054	0.94 (0.78, 1.13) 0.4888
	MPV (grouped by quartile)			
	Q 1	Ref	Ref	Ref
	02	0 83 (0 41, 1 66) 0 5955	0.82 (0.41, 1.65)	0.69 (0.32, 1.51)
	X 2	0.00 (0.11, 1.00) 0.0500	0.5753	0.3554
	03	0.49 (0.22, 1.10) 0.0839	0.48 (0.21, 1.08)	0.49 (0.20, 1.18)
		0.49 (0.22, 1.10) 0.0839	0.0758	0.1098
	Q4	0.76 (0.38, 1.56) 0.4585	0.78 (0.38, 1.59)	0.94 (0.42, 2.07)
			0.4883	0.8734
	P for trend	0.2663	0.2787	0.6522

Abbreviation:

RR: Relative risk

CI: Confidence interval

Non-adjusted model: No covariates were adjusted for

Minimally-adjusted model: We only adjusted for age and sex

Fully-adjusted model: We adjusted for all covariates presented in table 1.

medRxiv preprint doi: https://doi.org/10.1101/2023.06.16.23291510; this version posted June 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Table 3: Exploring the non-linear relationship between MPV and all-cause mortality

	BMI (kg/m ²) grouping	<28	>=28	Total
	Fitting model by standard binary	1.03 (0.83, 1.27)	1.00 (0.00, Inf)	1.01 (0.81, 1.25)
	logistic regression model	0.8177	1.0000	0.9558
	Fitting model by two-piecewise linear	r		
	model			
medRxiv preprint doi: (which was not co	Inflection point(95%CI) https://doi.org/10.1101/2023.06.16.23291510; this version posted J ertified by peer review) is the author/funder, who has granted medF	9.7 une 20, 2023. The copyright holde Rxiv a license to display the preprir	9.4 r for this preprint it in perpetuity.	9.8
		0.08 (0.03, 0.22)	1.00 (0.00, Inf)	0.09 (0.03, 0.24)
	< inflection point	<0.0001	1.0000	<0.0001
		1.29 (1.02, 1.64)	1.00 (0.00, Inf)	1.27 (1.01, 1.61)
	> inflection point	0.0334	1.0000	0.0434
	P for log likelihood ratio test	< 0.001	1.000	< 0.001

We adjusted for all covariates presented in table 1.

Figure